Sensitisation of trail-resistant ovarian cancer cell line SKOV-3 to carboplatin by HGS-ETR1 and HGS-ETR2

被引：0
|
作者：
Krishnan, B [1 ]
Ormerod, MG [1 ]
Kaye, SB [1 ]
Jackman, AL [1 ]
机构：
[1] Inst Canc Res, London SW3 6JB, England
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：43 / 44
页数：2
相关论文
共 30 条
  • [1] Combination treatment of colorectal tumours with the apoptosis-induced TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: In vitro and in vivo effect
    Marini, P
    Schiller, D
    Kauder, S
    Denzinger, S
    Welz, S
    Jendrossek, V
    Budach, W
    Belka, C
    STRAHLENTHERAPIE UND ONKOLOGIE, 2005, 181 : 77 - 77
  • [2] Human agonistic anti-TRAIL receptor antibodies, HGS-ETR1 and HGS-ETR2, induce apoptosis in diverse hematological tumor lines.
    Johnson, RL
    Huang, XL
    Fiscella, M
    Cole, C
    Pukac, L
    Von Kerczek, A
    Humphreys, R
    Grzegorzewski, KJ
    Gallant, G
    Albert, V
    BLOOD, 2003, 102 (11) : 891A - 891A
  • [3] In vitro and in vivo effects after combined treatment of colorectal tumors with apoptosis inducing trail receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy
    Marini, P
    Denzinger, S
    Kauder, S
    Schiller, D
    Welz, S
    Jendrossek, V
    Budach, W
    Belka, C
    RADIOTHERAPY AND ONCOLOGY, 2006, 78 : S75 - S75
  • [4] Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells
    Menoret, Emmanuelle
    Gomez-Bougie, Patricia
    Geffroy-Luseau, Alexandrine
    Daniels, Sylvanne
    Moreau, Philippe
    Le Gouill, Steven
    Harousseau, Jean-Luc
    Bataille, Regis
    Amiot, Martine
    Pellat-Deceunynck, Catherine
    BLOOD, 2006, 108 (04) : 1346 - 1352
  • [5] Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy:: enhanced effects in vitro and dose-dependent growth delay in vivo
    Marini, P.
    Denzinger, S.
    Schiller, D.
    Kauder, S.
    Welz, S.
    Humphreys, R.
    Daniel, P. T.
    Jendrossek, V.
    Budach, W.
    Belka, C.
    ONCOGENE, 2006, 25 (37) : 5145 - 5154
  • [6] Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo
    P Marini
    S Denzinger
    D Schiller
    S Kauder
    S Welz
    R Humphreys
    P T Daniel
    V Jendrossek
    W Budach
    C Belka
    Oncogene, 2006, 25 : 5145 - 5154
  • [7] Treatment of colorectal tumors with apoptosis inducing TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 in combination with radiotherapy:: additive effects in vitro and dose dependent growth delay in vivo
    Marini, P.
    Schiller, D.
    Kauder, S.
    Denzinger, S.
    Welz, S.
    Jendrossek, V.
    Budach, W.
    Belka, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 45 - 45
  • [8] Novel, agonistic, human anti-TRAIL receptor monoclonal antibodies, HGS-ETR1 and HGS-ETR2, are capable of potently inducing tumor regression and growth inhibition as single agents and in combination with chemotherapeutic agents in models of human NSCLC.
    Humphreys, R
    Shepard, L
    Zhang, YQ
    Huang, X
    Johnson, R
    McCormick, K
    Blondel, O
    Kanakaraj, P
    Grzegorzewski, KG
    Fox, NL
    Albert, V
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6157S - 6157S
  • [9] HGS-ETR2-ST02: A phase 1 clinical trial of HGS-ETR2, a fully-human activating monoclonal antibody to TRAIL-R2, in patients with advanced solid tumors.
    Sarantopoulos, J
    Wakelee, H
    Mita, M
    Fitzgerald, A
    Hill, M
    Fox, NL
    Howard, T
    Ullrich, S
    Tolcher, AW
    Sikic, B
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9104S - 9104S
  • [10] HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
    L Pukac
    P Kanakaraj
    R Humphreys
    R Alderson
    M Bloom
    C Sung
    T Riccobene
    R Johnson
    M Fiscella
    A Mahoney
    J Carrell
    E Boyd
    X T Yao
    L Zhang
    L Zhong
    A von Kerczek
    L Shepard
    T Vaughan
    B Edwards
    C Dobson
    T Salcedo
    V Albert
    British Journal of Cancer, 2005, 92 : 1430 - 1441
123